阿尔尼拉姆制药公司
ALNY452.107USD
+10.407+2.36%
交易中 （美东）报价延迟15分钟
59.58B总市值
1367.70市盈率 TTM
关于 阿尔尼拉姆制药公司 公司
Alnylam Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司致力于发现、开发、制造和商业化基于核糖核酸干扰 (RNAi) 的新型疗法。其上市产品包括用于治疗成人遗传性转甲状腺素介导性淀粉样变性 (hATTR) 伴多发性神经病的 AMVUTTRA (vutrisiran)；用于治疗成人 hATTR 淀粉样变性伴多发性神经病的 ONPATTRO (patisiran)；用于治疗成人急性肝卟啉症的 GIVLAARI (givosiran)；用于治疗 1 型原发性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴诺华公司开发和商业化的 Leqvio (inclisiran)，用于治疗成人高胆固醇血症或混合性血脂异常。该公司的临床开发项目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。该公司正在开发 Cemdisiran 来治疗补体介导的疾病。
阿尔尼拉姆制药公司简介
公司代码ALNY
公司名称Alnylam Pharmaceuticals Inc
上市日期May 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
员工数量2230
证券类型Ordinary Share
年结日May 28
公司地址675 W Kendall St
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142-1168
电话16175518200
网址https://www.alnylam.com/
公司代码ALNY
上市日期May 28, 2004
CEODr. Yvonne L. Greenstreet, M.D.
阿尔尼拉姆制药公司公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
65.82K
+16.23%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
65.82K
+16.23%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
54.11K
+7.83%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
27.44K
+5.56%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
--
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
业务USD
名称
营收
占比
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
其他
50.81M
6.57%
地区USD
名称
营收
占比
United States
454.57M
58.75%
Europe
157.01M
20.29%
Net revenues from collaborations
61.50M
7.95%
Rest of World
60.63M
7.84%
Royalty revenue
39.98M
5.17%
业务
地区
业务USD
名称
营收
占比
AMVUTTRA
491.95M
63.59%
GIVLAARI
80.85M
10.45%
ONPATTRO
52.54M
6.79%
Other
50.67M
6.55%
OXLUMO
46.87M
6.06%
其他
50.81M
6.57%
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Capital World Investors
12.72%
Fidelity Management & Research Company LLC
11.39%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.44%
BlackRock Institutional Trust Company, N.A.
4.94%
其他
55.28%
持股股东
持股股东
占比
Capital World Investors
12.72%
Fidelity Management & Research Company LLC
11.39%
The Vanguard Group, Inc.
10.22%
Capital Research Global Investors
5.44%
BlackRock Institutional Trust Company, N.A.
4.94%
其他
55.28%
股东类型
持股股东
占比
Investment Advisor
68.97%
Investment Advisor/Hedge Fund
21.97%
Hedge Fund
3.70%
Research Firm
1.84%
Sovereign Wealth Fund
1.63%
Bank and Trust
1.27%
Pension Fund
1.27%
Corporation
1.05%
Individual Investor
0.42%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1364
130.85M
99.04%
-1.89M
2025Q2
1300
131.78M
100.54%
-3.28M
2025Q1
1315
132.55M
101.67%
-2.42M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital World Investors
16.81M
12.82%
+55.38K
+0.33%
Jun 30, 2025
Fidelity Management & Research Company LLC
15.05M
11.48%
+427.38K
+2.92%
Jun 30, 2025
The Vanguard Group, Inc.
13.24M
10.1%
+238.24K
+1.83%
Jun 30, 2025
Capital Research Global Investors
7.19M
5.49%
+36.93K
+0.52%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.53M
4.98%
-199.00K
-2.96%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
4.28M
3.27%
-136.87K
-3.10%
Jun 30, 2025
JP Morgan Asset Management
1.79M
1.37%
-87.08K
-4.64%
Jun 30, 2025
Dodge & Cox
3.20M
2.44%
-154.67K
-4.61%
Jun 30, 2025
State Street Investment Management (US)
3.17M
2.42%
-193.48K
-5.75%
Jun 30, 2025
T. Rowe Price Associates, Inc.
3.05M
2.32%
-359.26K
-10.55%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Global X Genomics & Biotechnology ETF
6.7%
ProShares Ultra Nasdaq Biotechnology
6.12%
Invesco Nasdaq Biotechnology ETF
5.99%
iShares Biotechnology ETF
5.42%
Franklin Genomic Advancements ETF
5.21%
VanEck Biotech ETF
4.84%
First Trust NYSE Arca Biotechnology Index Fund
4.5%
American Century Focused Dynamic Growth ETF
4.11%
Pinnacle Focused Opportunities ETF
3.71%
Invesco NASDAQ Next Gen 100 ETF
3.42%
查看更多
Global X Genomics & Biotechnology ETF
占比6.7%
ProShares Ultra Nasdaq Biotechnology
占比6.12%
Invesco Nasdaq Biotechnology ETF
占比5.99%
iShares Biotechnology ETF
占比5.42%
Franklin Genomic Advancements ETF
占比5.21%
VanEck Biotech ETF
占比4.84%
First Trust NYSE Arca Biotechnology Index Fund
占比4.5%
American Century Focused Dynamic Growth ETF
占比4.11%
Pinnacle Focused Opportunities ETF
占比3.71%
Invesco NASDAQ Next Gen 100 ETF
占比3.42%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
